The U.S. Section 232 pharmaceutical tariff regime has entered a critical new phase. Under Proclamation 11020 issued on April 2, 2026, imports of patented pharmaceutical articles and their associated ingredients from all companies—not just those named in Annex III—became subject to additional duties effective September 29, 2026, at 12:01 a.m. Eastern Time. For chemical suppliers and their U.S. customers, this represents a fundamental shift in landed-cost calculation that cannot be resolved by product name alone.
What Is Changing
The April 2 proclamation imposed a baseline 100% ad valorem tariff on patented pharmaceutical articles and their active pharmaceutical ingredients (APIs) and key starting materials classified under specified HTSUS headings in Chapters 29 and 30. Annex III companies faced these duties from July 31, 2026. All other companies—including most specialty chemical suppliers serving the pharmaceutical supply chain—now face the same obligations.
Critically, generic pharmaceuticals and their associated ingredients remain exempt from these additional duties. However, the exemption hinges on FDA classification, not commercial labeling. A product marketed as a “research reagent” or “general intermediate” can still fall within Annex I coverage if it functions as a patented drug ingredient under the proclamation’s definitions.
Why Chemical Importers Must Reassess
The tariff’s scope is narrower than the original Section 232 investigation, which had contemplated coverage of all pharmaceutical imports. Proclamation 11020 limits tariffs to a subset of products listed in Annex I that are also subject to a valid, unexpired U.S. patent and listed in FDA’s Approved Drug Products publications. Products classified under Annex IV HTSUS codes receive a zero Section 232 rate, including many antibiotics, certain cardiovascular medicines, and specified chemical contraceptives.
This means that two products with similar chemical descriptions can face radically different duty outcomes based on:
- HTS classification at the 10-digit level
- Patent status of the end drug product
- Country of origin (EU, Japan, Korea, Switzerland, and Liechtenstein products may qualify for reduced 15% rates under trade agreements)
- Importer identity and onshoring/MFN agreements that can reduce rates to 20% or even 0%
What XinChem Customers Should Verify Before Quoting
For U.S. inquiries involving pharmaceutical-related chemicals, XinChem recommends confirming four data points before finalizing quotes or freight terms:
- CAS number and HTS classification — Confirm the 10-digit HTSUS code and whether it appears in Annex I or Annex IV of Proclamation 11020. Chapter 99 reporting is now mandatory for all covered Chapter 29 and 30 entries.
- End-use and patent status — Determine whether the imported material will be used in the manufacture of a patented drug product. A chemical intermediate with no patented end-use may remain outside the tariff’s scope.
- Importer eligibility — Identify whether the U.S. importer has an approved onshoring plan, an MFN pricing agreement, or qualifies for country-specific reduced rates.
- Exemption basis — Document any claimed exemption under Annex IV, orphan drug provisions, or specialty product categories. The lowest applicable rate must be applied when multiple rates could govern a single entry.
Customers should direct specific classification and entry decisions to their trade compliance counsel or licensed customs broker. XinChem will provide available technical documentation—including synthesis pathway information and intended-use statements—to support accurate HTS determination. However, tariff liability and entry filing responsibility remain with the importer of record.
The Bottom Line
The Section 232 pharmaceutical tariff is now fully operational for all companies as of September 29, 2026. For chemical buyers and their suppliers, the operative question is no longer whether tariffs apply, but which tariff applies to this specific product, from this specific origin, for this specific end use. Product-name assumptions are no longer sufficient. Classification-level diligence is now a prerequisite for accurate landed-cost planning.
XinChem remains committed to providing transparent documentation and responsive support as U.S. customers navigate this evolving compliance landscape. For product-specific inquiries, contact our export compliance team.
Contact us today to start your partnership with XinChem!
Website: www.xinchem.com
Email: sales1@xinchem.com
WhatsApp: +86 18049800532
Post time: Oct-07-2026